Pharmaceutical composition containing pulsatilla chinensis extract and application thereof

The technology of Pulsatilla and its extract, applied in the field of medicine, can solve problems such as unclear effect of Pulsatilla, and achieve the effects of reducing disease activity index, improving abundance, and repairing intestinal mucosal damage.

Inactive Publication Date: 2021-09-17
北京浩鼎瑞生物科技有限公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the specific role of pulsatilla in the treatment of ulcerative colitis is unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing pulsatilla chinensis extract and application thereof
  • Pharmaceutical composition containing pulsatilla chinensis extract and application thereof
  • Pharmaceutical composition containing pulsatilla chinensis extract and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Preparation of Pulsatilla Pulsatilla Water Extract (PRW): 250g of Pulsatilla Pulsatillae was purchased from Tongrentang, extracted at 105°C for 1.5 hours in a 1:6 (g / mL) ratio of medicine and water, repeated twice, concentrated and evaporated to the original 1 / 4 of the volume, and then vacuum freeze-dried (-80, -0.06kPa, 48h) for future use.

[0047] Experimental group:

[0048] Female C57BL / 6J mice aged 6-8 weeks were provided by the Animal Center of Shanxi Provincial People's Hospital. The colitis model was established by dextran sulfate sodium salt (DSS) induction. Thirty-six mice were randomly divided into control group, DSS group and PR group. Except for the control group, the mice in the other groups were treated with 3% w / v DSS in drinking water to induce colitis for 7 days.

[0049] Specifically: control group: normal drinking water. DSS group: DSS (40000 kDa; Seebio, Shanghai, China) was added as drinking water at a ratio of 3% w / v. PR group: 3% DSS drinkin...

Embodiment 2

[0051] Embodiment 2 PR is to the improvement of colitis symptom

[0052] Evaluation of colitis: The weight loss, stool consistency and fecal blood content of mice in each group were recorded. Scores for weight loss, stool consistency, and fecal blood content were added to calculate the total disease activity index (DAI). DAI is a clinical parameter reflecting the severity of colitis, and each parameter is scored as follows: weight loss (0: 20%), stool consistency (0: normal; 2: loose stool; 4: diarrhea), blood content in stool (0: occult negative; 2: occult positive; 4: massive bleeding).

[0053] At the end of the experiment, the colon segment was excised, and the length from the ileocecal to the anal verge was measured. Subsequently, formalin (10%) was used for tissue fixation, followed by paraffinization of conical tissue, staining with eosin and hematoxylin (H&E), and blind scoring by an experienced pathologist. Mucus is stained by Meyer mucin.

[0054] The result is as...

Embodiment 3

[0055] Example 3 The Repair Effect of PR on Colonic Mucosa Damage

[0056] Immunohistochemical analysis: Paraffin-embedded colon slides (4 μm) were deparaffinized and subjected to antigen retrieval by microwave heating in 10 mM citrate buffer (pH 6.0) for 10 min. After the slides were washed with PBS, they were washed with 3% H 2 o 2 Incubate with goat serum for 10min and 15min at room temperature. The treated slides were added with primary antibodies ZO-1 (1:500, Proteintech, Wuhan, China), occludin (1:500, Abclonal, Wuhan, China), claudin 1 (1:500, Abclonal, Wuhan, China), MUC2 (1:500 , Proteintech, Wuhan, China) and MUC3A (1:500, Boster, Wuhan, China) were incubated overnight at 4°C. Add biotinylated rabbit secondary antibody and incubate for 30 minutes at room temperature. After 30 min incubation with streptavidin-HRP, sections were stained with DAB substrate for 5 min.

[0057] The results of immunochemical staining showed ( figure 2 ), PR treatment maintained prop...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical composition containing a pulsatilla chinensis extract and application thereof, wherein the pulsatilla chinensis extract is a water extract. The invention proves that the pulsatilla chinensis water extract has the effects of recovering the diversity of intestinal mucosa flora, protecting the effect of colonic mucosa lactobacillus reuteri from being damaged, improving the intestinal barrier function and inhibiting the expression of inflammatory factors, and can be used for treating ulcerative colitis. The invention proves the treatment effect of the pulsatilla chinensis extract on ulcerative colitis for the first time. Compared with a traditional compound preparation, the pulsatilla chinensis root extract disclosed by the invention is more convenient to use, and can avoid toxic and side effects caused by western medicine treatment.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a pharmaceutical composition containing Pulsatilla pulsatilla extract, and the application of Pulsatilla pulsatillae extract in repairing colonic mucosal damage, inhibiting the secretion of inflammatory factors, improving the severity of colitis, and the like. Background technique [0002] Ulcerative colitis (UC) is a chronic, non-specific intestinal inflammatory disease of unknown etiology, which is a type of inflammatory bowel disease. The course of the disease is long and often recurrent. In recent decades, the incidence of UC has gradually increased worldwide. At present, aminosalicylic acid, steroid hormones, and immunosuppressants are mainly used to treat UC, but these drugs are not suitable for long-term use, and it is difficult to effectively prevent and treat them. [0003] Intestinal barrier dysfunction is closely related to the pathogenesis of UC. Studies have show...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/71A61K9/19A61P1/04A61P1/00A61P29/00A61M3/02A61K35/747
CPCA61K36/71A61K35/747A61K9/19A61K9/0031A61P1/04A61P1/00A61P29/00A61M3/0279A61K2236/331A61K2300/00Y02A50/30
Inventor 李亚峰董丽娜张洵孙龙
Owner 北京浩鼎瑞生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap